Novapeutics LLC

New Jersey
United States

Treating type 2 diabetes using menin inhibitors to regenerate insulin producing beta cells

Pharmaceuticals & Personal Care


We are developing a novel small molecule diabetes therapeutic to enhance endogenous insulin producing beta cell regeneration in diabetes patients. We are determining the impact of the identified lead compounds (CDH1‐2) on beta cell regeneration and to optimize improved compounds based on the crystal structure of drug target menin.